EGFR and lung adenocarcinoma: The G719X mutation showed intermediate sensitivity to first-generation TKIs, like gefitinib and erlotinib.[11,12] Previous work also showed that the second generation of EGFR TKIs, like neratinib and afatinib, effectively treat lung adenocarcinoma with the EGFR G719X point mutation.[13,14]